RT Journal Article
SR Electronic
T1 Epidemiological profile study of COVID-19 in West African countries: Nigeria, Senegal, Mauritania, Cape Verde and Mali
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.31.21258118
DO 10.1101/2021.05.31.21258118
A1 Ba, Mouhamadou Faly
A1 Diop, Boly
A1 Bassoum, Oumar
A1 Sougou, Ndèye Marème
A1 Niang, Khadim
A1 Bonnet, Emmanuel
A1 Ridde, Valéry
A1 Faye, Adama
YR 2021
UL http://medrxiv.org/content/early/2021/06/01/2021.05.31.21258118.abstract
AB Introduction The COVID-19 pandemic was first reported in West Africa on 27 February 2020 in Nigeria. It subsequently spread to other countries in the region. The objective of this study is to analyze the epidemiological profile of COVID-19 in West Africa from the first reported case to 31 January 2021.Method We publicly used available data from reliable sources and from the “COVID-19R” package. We used epidemic curves to describe the trends in the daily evolution of confirmed cases and deaths of COVID-19 in West Africa and specifically in the five countries. The reproduction rate and evolution rates were calculated from these trends.Results As of 31 January 2021, West Africa had 342,938 confirmed cases of COVID-19 with 4,496 deaths. Nigeria had 131,242 cases with 1,586 deaths. Senegal had 26,523 cases with 628 deaths. The case-fatality rate in Mali was 4.08% and the attack rate in Cape Verde was 2587 cases per 100,000 inhabitants. In Nigeria, Senegal, Mauritania and Mali, the epidemic curves supported by the evolution rates showed an increase in confirmed cases and deaths of COVID-19 during December 2020 and January 2021 compared to the last two months. The effective reproduction rates (Re) inferred a slowdown in virus transmission (Re < 1) in these countries except for Senegal.Conclusion The results showed that COVID-19 was still circulating in some West African countries in late 2020 and early 2021. By improving the health system and with context-specific public health interventions and vaccination, these countries should effectively control COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was not requiredAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request to the authors.